RecruitingNCT04639635

CNGB1 and Allied Disorders

Study of CNGB1 Retinitis Pigmentosa and Allied Hereditary Disorders


Sponsor

Columbia University

Enrollment

20 participants

Start Date

Mar 14, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes. Treatment by gene therapy could prevent blindness in cases of inherited retinal dystrophies including RP. In the future RP due to mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor degeneration involves a slow loss of rod photoreceptor cells. This provides a wide window of opportunity for the identification of patients and initiation of treatment. Our efforts are directed toward developing gene therapy as a treatment. To this end, our objective is to better understand the disease process of CNGB1-RP and other allied inherited disorders so that we can develop clinical tests to measure the outcomes of treatment.


Eligibility

Inclusion Criteria2

  • Diagnosis of CNGB1-associated RP by study physician, who are trained retinal specialists in the university clinic
  • Must be able to commit to 4 follow-up study visits (3 years)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention, this is a natural history progression study

The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.


Locations(6)

Dr. Stephen H. Tsang

New York, New York, United States

Wills Eye Hospital

Philadelphia, Pennsylvania, United States

Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts

Paris, France

Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich

München, Bavaria, Germany

Eberhard Karls University Tubingen

Tübingen, Germany

Moorfields Eye Hospital NHS Foundation Trust

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04639635